



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dean Y. Li

Serial No: 09/921,771

Filed: August 3, 2001

For: Manipulation of Arterial-Venous
Identity

Attorney Docket No. HYDR-P01-003

Art Unit: 1636

Examiner: C. Qian

#12/a
Zuta
3/12/03

RECEIVED
MAR 12 2003
TECH CENTER 1600/29

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

January 31, 2003

Date of Signature
and of Mail Deposit

Ginny Blundell

Commissioner for Patents
Washington, D.C. 20231

REPLY UNDER 37 CFR 1.111

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed August 1, 2002, in connection with the above application. Please enter the following amendments:

In the specification:

◇◇ Please replace paragraph [0042] with the following:

A Those skilled in the art will readily recognize that the various genes introduced into endothelial cells, using either viral or non-viral methods, may be operably linked to control elements such as promoters and enhancers, that are capable of driving or repressing gene expression under appropriate conditions. Termination signals, such as polyadenylation sites, can also be included. Control elements, such as inducible promoters, that allow controlled expression of the gene of interest are available. For example, an ecdysone-inducible promoter can be utilized to regulate gene expression. (See, e.g., Statagene's; Complete Control™ Inducible Mammalian Expression System Instruction Manual – available online at